RecruitingRecruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972 · Novartis
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-blind, Placebo-controlled Extension Study, Followed by a Study Treatment Withdrawal or Open-label Period, to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
About this study
The purpose of this extension study is to evaluate long-term safety and tolerability of ianalumab administered s.c. monthly or quarterly, compared to monthly placebo, in adolescent and adult participants with anti-nuclear antibody (ANA)-positive systemic lupus erythematosus of moderate-to-severe disease activity, who have completed either CVAY736F12301 (SIRIUS-SLE 1) or CVAY736F12302 (SIRIUS-SLE 2) core studies.
This extension study will last up to 7 years and includes the following three treatment periods:
* a 3-year double-blind, randomized, placebo-controlled treatment period, evaluating the safety and efficacy of ianalumab or placebo (Period 1);
* followed by a 2-year treatment period evaluating safety and efficacy of treatment withdrawal and open-label ianalumab administered s.c. monthly.
* and an up to 2-year open-label, safety monitoring period (Period 3).
Eligibility criteria
Key Inclusion Criteria:
* Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants \<18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
* Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
* In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.
Key Exclusion Criteria:
* Use of prohibited therapies.
* Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
* Plans for administration of live vaccines during the study period.
* Pregnant or nursing (lactating) women.
Other protocol-defined inclusion/exclusion criteria may apply.
Study design
Enrollment target: 550 participants
Allocation: randomized
Masking: quadruple
Age groups: child, adult, older_adult
Timeline
Starts: 2024-05-21
Estimated completion: 2034-10-02
Last updated: 2026-11-09
Interventions
Drug: PlaceboDrug: Ianalumab
Primary outcomes
- • Number of treatment-emergent Adverse events/Serious Adverse events (through study completion, up to approximately 324 weeks)
Sponsor
Novartis Pharmaceuticals · industry
Contacts & investigators
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · 1-888-669-6682
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · +41613241111
InvestigatorNovartis Pharmaceuticals · study_director, Novartis Pharmaceuticals
All locations (167)
Pinnacle Research Group LlcRecruiting
Anniston, Alabama, United States
Providence Medical CenterRecruiting
Burbank, California, United States
Advanced Medical ResearchRecruiting
La Palma, California, United States
Millennium Clinical TrialsActive Not Recruiting
Westlake Village, California, United States
University of Colorado DenverRecruiting
Aurora, Colorado, United States
Clinical Res Of W FloridaRecruiting
Clearwater, Florida, United States
GNP ResearchRecruiting
Cooper City, Florida, United States
Homestead Assoc In Research IncRecruiting
Homestead, Florida, United States
IRIS Research and DevelopmentRecruiting
Plantation, Florida, United States
Clinical Research of West Florida IncRecruiting
Tampa, Florida, United States
Parris and Associates RheumatologyRecruiting
Lawrenceville, Georgia, United States
Robert A Hozman MD SCCompleted
Skokie, Illinois, United States
Willow Rheumatology WellnessRecruiting
Willowbrook, Illinois, United States
Accurate Clinical ResearchRecruiting
Lake Charles, Louisiana, United States
UMC New OrleansActive Not Recruiting
New Orleans, Louisiana, United States
University Of MarylandActive Not Recruiting
Baltimore, Maryland, United States
Henry Ford HealthRecruiting
Detroit, Michigan, United States
Ahmed Arif Medical Research CenterRecruiting
Grand Blanc, Michigan, United States
Paramount Med Rsrch and Consult LLCRecruiting
Middleburg Heights, Ohio, United States
University Of PittsburghRecruiting
Pittsburgh, Pennsylvania, United States
West Tennessee Research InstituteRecruiting
Jackson, Tennessee, United States
Shelby Research LLCRecruiting
Memphis, Tennessee, United States
Novel Research LLCRecruiting
Bellaire, Texas, United States
Accurate Clinical ResearchRecruiting
League City, Texas, United States
Epic Medical ResearchRecruiting
Red Oak, Texas, United States
Novartis Investigative SiteRecruiting
La Plata, Buenos Aires, Argentina
Novartis Investigative SiteRecruiting
Quilmes, Buenos Aires, Argentina
Novartis Investigative SiteActive Not Recruiting
San Miguel, Buenos Aires, Argentina
Novartis Investigative SiteActive Not Recruiting
San Miguel, Tucumán Province, Argentina
Novartis Investigative SiteActive Not Recruiting
Caba, Argentina
Novartis Investigative SiteRecruiting
Caba, Argentina
Novartis Investigative SiteActive Not Recruiting
San Miguel de Tucumán, Argentina
Novartis Investigative SiteRecruiting
Maroochydore, Queensland, Australia
Novartis Investigative SiteRecruiting
Vitória, Espírito Santo, Brazil
Novartis Investigative SiteRecruiting
Salvador, Estado de Bahia, Brazil
Novartis Investigative SiteActive Not Recruiting
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative SiteRecruiting
Curitiba, Paraná, Brazil
Novartis Investigative SiteActive Not Recruiting
Niterói, Rio de Janeiro, Brazil
Novartis Investigative SiteRecruiting
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative SiteRecruiting
Barretos, São Paulo, Brazil
Novartis Investigative SiteActive Not Recruiting
São Paulo, São Paulo, Brazil
Novartis Investigative SiteActive Not Recruiting
São Paulo, São Paulo, Brazil
Novartis Investigative SiteRecruiting
Salvador, Brazil
Novartis Investigative SiteRecruiting
Plovdiv, Bulgaria, Bulgaria
Novartis Investigative SiteRecruiting
Sofia, Bulgaria
Novartis Investigative SiteActive Not Recruiting
Vancouver, British Columbia, Canada
Novartis Investigative SiteActive Not Recruiting
Toronto, Ontario, Canada
Novartis Investigative SiteRecruiting
Rimouski, Quebec, Canada
Novartis Investigative SiteRecruiting
Valdivia, Los Ríos Region, Chile
Novartis Investigative SiteRecruiting
Santiago, RM, Chile
Novartis Investigative SiteRecruiting
Santiago, Santiago Metropolitan, Chile
Novartis Investigative SiteRecruiting
Guangzhou, Guangdong, China
Novartis Investigative SiteRecruiting
Guangzhou, Guangdong, China
Novartis Investigative SiteRecruiting
Shantou, Guangdong, China
Novartis Investigative SiteRecruiting
Nanjing, Jiangsu, China
Novartis Investigative SiteRecruiting
Suzhou, Jiangsu, China
Novartis Investigative SiteActive Not Recruiting
Nanchang, Jiangxi, China
Novartis Investigative SiteRecruiting
Pingxiang, Jiangxi, China
Novartis Investigative SiteRecruiting
Changchun, Jilin, China
Novartis Investigative SiteRecruiting
Linyi, Shandong, China
Novartis Investigative SiteRecruiting
Chengdu, Sichuan, China
Novartis Investigative SiteRecruiting
Ürümqi, Xinjiang, China
Novartis Investigative SiteRecruiting
Ningbo, Zhejiang, China
Novartis Investigative SiteRecruiting
Wenzhou, Zhejiang, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Shanghai, China
Novartis Investigative SiteRecruiting
Xinxiang, China
Novartis Investigative SiteActive Not Recruiting
Medellín, Antioquia, Colombia
Novartis Investigative SiteActive Not Recruiting
Barranquilla, Atlántico, Colombia
Novartis Investigative SiteActive Not Recruiting
Chía, Cundinamarca, Colombia
Novartis Investigative SiteActive Not Recruiting
Bucaramanga, Santander Department, Colombia
Novartis Investigative SiteRecruiting
Cali, Valle del Cauca Department, Colombia
Novartis Investigative SiteActive Not Recruiting
Bogotá, Colombia
Novartis Investigative SiteRecruiting
Brno, Czechia
Novartis Investigative SiteRecruiting
Prague, Czechia
Novartis Investigative SiteRecruiting
Uherské Hradiště, Czechia
Novartis Investigative SiteRecruiting
Montpellier, France
Novartis Investigative SiteActive Not Recruiting
Paris, France
Novartis Investigative SiteActive Not Recruiting
Paris, France
Novartis Investigative SiteRecruiting
Toulouse, France
Novartis Investigative SiteRecruiting
Toulouse, France
Novartis Investigative SiteWithdrawn
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative SiteRecruiting
Leipzig, Saxony, Germany
Novartis Investigative SiteRecruiting
Guatemala City, Departamento de Guatemala, Guatemala
Novartis Investigative SiteRecruiting
Guatemala City, Guatemala
Novartis Investigative SiteRecruiting
Székesfehérvár, Fejér, Hungary
Novartis Investigative SiteRecruiting
Budapest, Hungary
Novartis Investigative SiteRecruiting
Gyula, Hungary
Novartis Investigative SiteRecruiting
Zalaegerszeg, Hungary
Novartis Investigative SiteRecruiting
Ahmedabad, Gujarat, India
Novartis Investigative SiteRecruiting
Ahmedabad, Gujarat, India
Novartis Investigative SiteRecruiting
Kozhikode, Kerala, India
Novartis Investigative SiteRecruiting
Kolhāpur, Maharashtra, India
Novartis Investigative SiteRecruiting
Nagpur, Maharashtra, India
Novartis Investigative SiteRecruiting
Nashik, Maharashtra, India
Novartis Investigative SiteRecruiting
Pune, Maharashtra, India
Novartis Investigative SiteRecruiting
Pune, Maharashtra, India
Novartis Investigative SiteRecruiting
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative SiteRecruiting
New Delhi, New Delhi, India
Novartis Investigative SiteRecruiting
Dehradun, Uttarakhand, India
Novartis Investigative SiteRecruiting
New Delhi, India
Novartis Investigative SiteActive Not Recruiting
Haifa, Israel
Novartis Investigative SiteRecruiting
Ramat Gan, Israel
Novartis Investigative SiteRecruiting
Cona, FE, Italy
Novartis Investigative SiteRecruiting
Padova, PD, Italy
Novartis Investigative SiteRecruiting
Pisa, PI, Italy
Novartis Investigative SiteRecruiting
Roma, RM, Italy
Novartis Investigative SiteRecruiting
Torino, TO, Italy
Novartis Investigative SiteActive Not Recruiting
Nagoya, Aichi-ken, Japan
Novartis Investigative SiteActive Not Recruiting
Nagoya, Aichi-ken, Japan
Novartis Investigative SiteActive Not Recruiting
Sapporo, Hokkaido, Japan
Novartis Investigative SiteActive Not Recruiting
Yokohama, Kanagawa, Japan
Novartis Investigative SiteRecruiting
Sendai, Miyagi, Japan
Novartis Investigative SiteRecruiting
Bunkyo-ku, Tokyo, Japan
Novartis Investigative SiteRecruiting
Chuo Ku, Tokyo, Japan
Novartis Investigative SiteActive Not Recruiting
Fuchū, Tokyo, Japan
Novartis Investigative SiteActive Not Recruiting
Shinjuku-ku, Tokyo, Japan
Novartis Investigative SiteActive Not Recruiting
tabashi City, Tokyo, Japan
Novartis Investigative SiteRecruiting
Miyazaki, Japan
Novartis Investigative SiteRecruiting
Osaka, Japan
Novartis Investigative SiteRecruiting
Ipoh, Perak, Malaysia
Novartis Investigative SiteRecruiting
León, Guanajuato, Mexico
Novartis Investigative SiteActive Not Recruiting
Guadalajara, Jalisco, Mexico
Novartis Investigative SiteActive Not Recruiting
Mexico City, Mexico City, Mexico
Novartis Investigative SiteActive Not Recruiting
Morelia, Michoacán, Mexico
Novartis Investigative SiteRecruiting
Mérida, Yucatán, Mexico
Novartis Investigative SiteActive Not Recruiting
México, Mexico
Novartis Investigative SiteRecruiting
Wroclaw, Lower Silesian Voivodeship, Poland
Novartis Investigative SiteRecruiting
Bydgoszcz, Poland
Novartis Investigative SiteRecruiting
Bydgoszcz, Poland
Novartis Investigative SiteRecruiting
Bytom, Poland
Novartis Investigative SiteRecruiting
Warsaw, Poland
Novartis Investigative SiteRecruiting
Warsaw, Poland
Novartis Investigative SiteRecruiting
Braga, Portugal
Novartis Investigative SiteRecruiting
Lisbon, Portugal
Novartis Investigative SiteRecruiting
Cluj-Napoca, Cluj, Romania
Novartis Investigative SiteRecruiting
Brasov, Romania
Novartis Investigative SiteRecruiting
Bucharest, Romania
Novartis Investigative SiteActive Not Recruiting
Bratislava, Slovakia
Novartis Investigative SiteActive Not Recruiting
Košice, Slovakia
Novartis Investigative SiteRecruiting
Pretoria, Gauteng, South Africa
Novartis Investigative SiteRecruiting
Cape Town, Western Cape, South Africa
Novartis Investigative SiteRecruiting
Cape Town, Western Cape, South Africa
Novartis Investigative SiteRecruiting
Somerset West, Western Cape, South Africa
Novartis Investigative SiteRecruiting
Umhlanga, South Africa
Novartis Investigative SiteCompleted
Gwangju, South Korea
Novartis Investigative SiteRecruiting
Seoul, South Korea
Novartis Investigative SiteRecruiting
Seoul, South Korea
Novartis Investigative SiteRecruiting
Santiago Compostela, A Coruna, Spain
Novartis Investigative SiteRecruiting
Badalona, Barcelona, Spain
Novartis Investigative SiteRecruiting
Santander, Cantabria, Spain
Novartis Investigative SiteRecruiting
Barcelona, Catalonia, Spain
Novartis Investigative SiteRecruiting
San Sebastian Reyes, Madrid, Spain
Novartis Investigative SiteRecruiting
Barcelona, Spain
Novartis Investigative SiteRecruiting
Madrid, Spain
Novartis Investigative SiteRecruiting
Valencia, Spain
Novartis Investigative SiteRecruiting
Kaohsiung City, Taiwan
Novartis Investigative SiteRecruiting
Taichung, Taiwan
Novartis Investigative SiteRecruiting
Taichung, Taiwan
Novartis Investigative SiteRecruiting
Taipei, Taiwan
Novartis Investigative SiteRecruiting
Taipei, Taiwan
Novartis Investigative SiteRecruiting
Taoyuan, Taiwan
Novartis Investigative SiteRecruiting
Songkhla, Hat Yai, Thailand
Novartis Investigative SiteRecruiting
Muang, Thailand, Thailand
Novartis Investigative SiteRecruiting
Bangkok, Thailand
Novartis Investigative SiteRecruiting
Bangkok, Thailand